RxDoctor Payments DataLook up a doctor →

David Bartov, MD

Interventional Cardiology · New Providence, NJNPI 1467616664

Payments from drug & device makers

$143,168in general payments, 2019–2025

Across 464 payments — averaging $308.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$132K
  • Abbott$2K
  • Cardiovascular Systems Inc.$2K
  • Penumbra, Inc.$1K
  • Shockwave Medical, Inc$853
  • Boston Scientific$749
  • plus $4K from 35 others

What the payments were for

  • Food & beverage$12,252100%
  • Entertainment$220%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$143,168 in reported general payments places this provider in the 90th percentile of 166 interventional cardiology providers in New Jersey.

See all interventional cardiology providers in New Jersey

Medicare billing

Part B allowed, 2024
$237,619
Medicare patients
894
Services billed
2,476

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban218$240,192
XareltoRivaroxaban44$51,395
EntrestoSacubitril/Valsartan45$43,761
BrilintaTicagrelor34$36,104
JardianceEmpagliflozin36$33,341
Repatha SureclickEvolocumab35$32,530
MultaqDronedarone Hcl19$30,150
FarxigaDapagliflozin Propanediol18$27,484
NexletolBempedoic Acid33$25,995
OzempicSemaglutide14$12,207
VascepaIcosapent Ethyl11$11,124
NexlizetBempedoic Acid/Ezetimibe17$10,546
Atorvastatin Calcium610$8,178
Metoprolol Succinate460$7,306
Ezetimibe129$3,489

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$230$240,192218 claims
AstraZenecaBrilinta, Farxiga$276$63,58852 claims
Johnson & JohnsonXarelto$305$51,39544 claims
NovartisEntresto$226$43,76145 claims
Esperion Therapeutics, Inc.Nexletol, Nexlizet$87$36,54150 claims
Boehringer IngelheimJardiance$50$33,34136 claims
Sanofi-aventis U.S. LLCMultaq$133$30,15019 claims
Novo NordiskOzempic$90$12,20714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 166 interventional cardiology providers in New Jersey.

Other interventional cardiology in New Providence

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →